Belite Bio CEO reports initial BLTE equity holdings
Belite Bio, Inc. director and CEO Lin Yu-Hsin has reported initial equity holdings, including stock options and share positions.
Rhea-AI Filing Summary
Belite Bio, Inc. director and CEO Lin Yu-Hsin has reported initial equity holdings, including stock options and share positions. The filing lists multiple stock options over ordinary shares with exercise prices from $0.4386 to $158.3600, expiring between 2030 and 2036. Several options are already fully vested, while others vest monthly through August 2028 and in annual tranches on January 9, 2027, January 9, 2028, and January 9, 2029. Lin also holds American depositary shares and ordinary shares directly. This Form 3 records existing positions; it does not show new buying or selling activity.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Lin Yu-Hsin
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | American depositary share | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 1,079,733 contracts (Direct);
American depositary share — 180,134 shares (Direct);
Ordinary Share — 172,949 shares (Direct)
Footnotes (9)
- F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer.
- F2. The option to purchase 206,954 ordinary shares had vested prior to March 18, 2026.
- F3. The option to purchase 27,778 ordinary shares had vested prior to March 18, 2026.
- F4. The option to purchase 145,833 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 20,834 ordinary shares in five equal and continuous monthly installments at the end of each month from March 2026 to July 2026, subject to continued service to the Issuer on each such date.
- F5. The option to purchase 83,334 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 125,000 ordinary shares in 18 monthly equal and continuous installments at the end of each month from March 2026 to August 2028, subject to continued service to the Issuer on each such date.
- F6. The option shall vest as to 200,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following February 12, 2025, subject to continued service to the Issuer on each such date.
- F7. The option to purchase 40,000 ordinary shares had vested prior to March 18, 2026.
- F8. The option to purchase 80,000 ordinary shares had vested prior to March 18, 2026.
- F9. The option shall vest (i) as to 50,000 ordinary shares on January 9, 2027, (ii) as to 50,000 ordinary shares on January 9, 2028, and (iii) as to 50,000 ordinary shares on January 9, 2029.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Lin Yu-Hsin report owning in Belite Bio (BLTE) on this Form 3?
Lin Yu-Hsin reports direct holdings of stock options, American depositary shares, and ordinary shares of Belite Bio. The options cover ordinary shares at various exercise prices and expiration dates, with some already vested and others scheduled to vest over several years.
Are there any buy or sell transactions in this Belite Bio (BLTE) Form 3?
No buy or sell transactions are shown; the entries are reported as holdings. The summary data indicates zero buy, sell, acquire, or dispose counts, with all ten entries classified as holding records and an overall neutral net buy/sell direction.
What are the key stock option terms reported for Belite Bio (BLTE) CEO Lin Yu-Hsin?
The Form 3 lists several stock options to buy ordinary shares with exercise prices from $0.4386 up to $158.3600, expiring between 2030-12-22 and 2036-01-08. Footnotes describe detailed vesting schedules, including monthly and annual vesting milestones.
How do the Belite Bio (BLTE) stock options for Lin Yu-Hsin vest over time?
Some options were fully vested before March 18, 2026, while others vest in equal monthly installments through July 2026 and August 2028. Another grant vests in three tranches on January 9, 2027, January 9, 2028, and January 9, 2029.
What does the Belite Bio (BLTE) Form 3 show about Lin Yu-Hsin’s derivative positions?
The derivative summary lists multiple stock option positions over ordinary shares, each with a specific exercise price and expiration date. These options represent unexercised rights to acquire shares in the future and remain outstanding as direct holdings according to the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
